BioCryst Pharmaceuticals | BCRX - Trade Creditors


BioCryst Pharmaceuticals reported $5.57M in Trade Creditors for its fiscal quarter ending in September of 2025.





Trade Creditors Change Date
Alnylam Pharmaceuticals USD 117.59M 15.2M Sep/2025
BioCryst Pharmaceuticals USD 5.57M 3.02M Sep/2025
Chugai Pharma JPY 127.25B 48.35B Dec/2025
Daiichi Sankyo JPY 568.5B 16.84B Dec/2025
DBV Technologies USD 39.82M 972K Sep/2025
Enanta Pharmaceuticals USD 1.88M 63K Dec/2025
Gilead Sciences USD 808M 226M Sep/2025
GlaxoSmithKline GBP 15.38B 294M Dec/2025
Glaxosmithkline GBP 21.07B 7.42B Sep/2025
Incyte USD 1.63B 1.46B Dec/2025
Ionis Pharmaceuticals USD 14.33M 8.47M Sep/2025
Karyopharm Therapeutics USD 5.39M 2.8M Sep/2025
Neurocrine Biosciences USD 119.9M 15.3M Sep/2025
Novavax USD 15.23M 35.37M Sep/2025
PTC Therapeutics USD 36.62M 169.69M Sep/2025
Regeneron Pharmaceuticals USD 5.83B 4.93B Dec/2025
Roche Holding CHF 5.78B 1.27B Dec/2025
Sarepta Therapeutics USD 94.02M 42.69M Sep/2025
Ultragenyx Pharmaceutical USD 40.57M 6.33M Sep/2025
Vertex Pharmaceuticals USD 4.03B 320.8M Sep/2025